Member News
The IHE Announces New CEO, Dr. Kate Harback
After an extensive search the Institute of Health Economics (IHE) Board of Directors has appointed Dr. Katherine (Kate) Harback as the new CEO and Executive Director for the IHE. Dr…. Read More
Member News
COLUMVI (Glofitamab for Injection) Receives Health Canada Authorization with Conditions for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
COLUMVI (glofitamab for injection) is the first fixed treatment duration CD20xCD3 T-cell engaging bispecific antibody approved in Canada, and globally, to treat diffuse large B-cell lymphoma[1,2,3] Authorization is based on… Read More
Member News
Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
All-oral, once-daily, fixed-duration combination regimen authorized for first-line treatment of CLL TORONTO, ON — /CNW/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued… Read More
Member News
Health Canada Approves First Treatment Option for Generalized Pustular Psoriasis Flares in Adults
Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.¹ In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules,… Read More
Member News
SBME’s 5th Annual Symposium
Join the UBC SBME for the SBME Symposium 2023 and be a part of our vibrant community of faculty, trainees, industry and hospital partners, and students as they continue to… Read More